Evaluation of the effect of probiotic prophylaxis in children with vesicoureteral reflux

Evaluation of the effect of probiotic prophylaxis in children with vesicoureteral reflux referred to the pediatric nephrology ward of Hamadan’s Besat Hospital, Iran.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140810018747N1

Enrollment

800

Registered

2021-06-27

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vesicoureteral-reflux. Vesicoureteral-reflux with reflux nephropathy with hydroureter, bilateral

Interventions

Intervention 1: Intervention group: Probiotic administration as prophylaxis, Yumogi probiotic {from Irianik company (Ardifarm Germany) containing Saccharomyces boulardii} with a dose of one 250 mg cap

Eligibility

Sex/Gender

All

Age

2 Months to 8 Years

Inclusion criteria

Inclusion criteria: All children 2 months to 8 years old who have been diagnosed with VUR by pediatric nephrologist based on imaging results

Exclusion criteria

Exclusion criteria: 1.Patients with obstructive causes 2.The presence of concomitant infections and inflammation 3.The presence of any known immune system disorders ,whether congenital or acquired 4.The presence of any known metabolic disorders.

Design outcomes

Primary

Measure	Time frame
Urinary tract infection recurrence in patients receiving prophylaxis. Timepoint: MONTHLY. Method of measurement: U/A,U/C.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Bazmamoun

Hamedan University of Medical Sciences

hbazmamoun@yahoo.com+98 81 3838 0426

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026